Prospective Evaluation of Germline Alterations in Patients With Exocrine Pancreatic Neoplasms
Identification of pathogenic germline alterations (PGAs) has important clinical and therapeutic implications in pancreas cancer. We performed comprehensive germline testing (GT) in an unselected prospective cohort of patients with exocrine pancreatic neoplasms with genotype and phenotype association...
Uložené v:
| Vydané v: | JNCI : Journal of the National Cancer Institute Ročník 110; číslo 10; s. 1067 |
|---|---|
| Hlavní autori: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | English |
| Vydavateľské údaje: |
United States
01.10.2018
|
| Predmet: | |
| ISSN: | 1460-2105, 1460-2105 |
| On-line prístup: | Zistit podrobnosti o prístupe |
| Tagy: |
Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
|
| Abstract | Identification of pathogenic germline alterations (PGAs) has important clinical and therapeutic implications in pancreas cancer. We performed comprehensive germline testing (GT) in an unselected prospective cohort of patients with exocrine pancreatic neoplasms with genotype and phenotype association to facilitate identification of prognostic and/or predictive biomarkers and examine potential therapeutic implications.
Six hundred fifteen unselected patients with exocrine pancreatic neoplasms were prospectively consented for somatic tumor and matched sample profiling for 410-468 genes. GT for PGAs in 76 genes associated with cancer susceptibility was performed in an "identified" manner in 356 (57.9%) patients and in an "anonymized" manner in 259 (42.1%) patients, using an institutional review board-approved protocol. Detailed clinical and pathological features, response to platinum, and overall survival (OS) were collected for the identified cohort. OS was analyzed with Kaplan-Meier curves.
PGAs were present in 122 (19.8%) of 615 patients involving 24 different genes, including BRCA1/2, ATM, PALB2, and multiple additional genes associated with the DNA damage response pathway. Of 122 patients with germline alterations, 41.8% did not meet current guidelines for GT. The difference in median OS was not statistically significant between patients with and without PGA (50.8 months, 95% confidence interval = 34.5 to not reached, two-sided P = .94). Loss of heterozygosity was found in 60.0% of BRCA1/2.
PGAs frequently occur in pancreas exocrine neoplasms and involve multiple genes beyond those previously associated with hereditary pancreatic cancer. These PGAs are therapeutically actionable in about 5% to 10% of patients. These data support routinely offering GT in all pancreatic ductal adenocarcimona patients with a broad panel of known hereditary cancer predisposition genes. |
|---|---|
| AbstractList | Identification of pathogenic germline alterations (PGAs) has important clinical and therapeutic implications in pancreas cancer. We performed comprehensive germline testing (GT) in an unselected prospective cohort of patients with exocrine pancreatic neoplasms with genotype and phenotype association to facilitate identification of prognostic and/or predictive biomarkers and examine potential therapeutic implications.BackgroundIdentification of pathogenic germline alterations (PGAs) has important clinical and therapeutic implications in pancreas cancer. We performed comprehensive germline testing (GT) in an unselected prospective cohort of patients with exocrine pancreatic neoplasms with genotype and phenotype association to facilitate identification of prognostic and/or predictive biomarkers and examine potential therapeutic implications.Six hundred fifteen unselected patients with exocrine pancreatic neoplasms were prospectively consented for somatic tumor and matched sample profiling for 410-468 genes. GT for PGAs in 76 genes associated with cancer susceptibility was performed in an "identified" manner in 356 (57.9%) patients and in an "anonymized" manner in 259 (42.1%) patients, using an institutional review board-approved protocol. Detailed clinical and pathological features, response to platinum, and overall survival (OS) were collected for the identified cohort. OS was analyzed with Kaplan-Meier curves.MethodsSix hundred fifteen unselected patients with exocrine pancreatic neoplasms were prospectively consented for somatic tumor and matched sample profiling for 410-468 genes. GT for PGAs in 76 genes associated with cancer susceptibility was performed in an "identified" manner in 356 (57.9%) patients and in an "anonymized" manner in 259 (42.1%) patients, using an institutional review board-approved protocol. Detailed clinical and pathological features, response to platinum, and overall survival (OS) were collected for the identified cohort. OS was analyzed with Kaplan-Meier curves.PGAs were present in 122 (19.8%) of 615 patients involving 24 different genes, including BRCA1/2, ATM, PALB2, and multiple additional genes associated with the DNA damage response pathway. Of 122 patients with germline alterations, 41.8% did not meet current guidelines for GT. The difference in median OS was not statistically significant between patients with and without PGA (50.8 months, 95% confidence interval = 34.5 to not reached, two-sided P = .94). Loss of heterozygosity was found in 60.0% of BRCA1/2.ResultsPGAs were present in 122 (19.8%) of 615 patients involving 24 different genes, including BRCA1/2, ATM, PALB2, and multiple additional genes associated with the DNA damage response pathway. Of 122 patients with germline alterations, 41.8% did not meet current guidelines for GT. The difference in median OS was not statistically significant between patients with and without PGA (50.8 months, 95% confidence interval = 34.5 to not reached, two-sided P = .94). Loss of heterozygosity was found in 60.0% of BRCA1/2.PGAs frequently occur in pancreas exocrine neoplasms and involve multiple genes beyond those previously associated with hereditary pancreatic cancer. These PGAs are therapeutically actionable in about 5% to 10% of patients. These data support routinely offering GT in all pancreatic ductal adenocarcimona patients with a broad panel of known hereditary cancer predisposition genes.ConclusionsPGAs frequently occur in pancreas exocrine neoplasms and involve multiple genes beyond those previously associated with hereditary pancreatic cancer. These PGAs are therapeutically actionable in about 5% to 10% of patients. These data support routinely offering GT in all pancreatic ductal adenocarcimona patients with a broad panel of known hereditary cancer predisposition genes. Identification of pathogenic germline alterations (PGAs) has important clinical and therapeutic implications in pancreas cancer. We performed comprehensive germline testing (GT) in an unselected prospective cohort of patients with exocrine pancreatic neoplasms with genotype and phenotype association to facilitate identification of prognostic and/or predictive biomarkers and examine potential therapeutic implications. Six hundred fifteen unselected patients with exocrine pancreatic neoplasms were prospectively consented for somatic tumor and matched sample profiling for 410-468 genes. GT for PGAs in 76 genes associated with cancer susceptibility was performed in an "identified" manner in 356 (57.9%) patients and in an "anonymized" manner in 259 (42.1%) patients, using an institutional review board-approved protocol. Detailed clinical and pathological features, response to platinum, and overall survival (OS) were collected for the identified cohort. OS was analyzed with Kaplan-Meier curves. PGAs were present in 122 (19.8%) of 615 patients involving 24 different genes, including BRCA1/2, ATM, PALB2, and multiple additional genes associated with the DNA damage response pathway. Of 122 patients with germline alterations, 41.8% did not meet current guidelines for GT. The difference in median OS was not statistically significant between patients with and without PGA (50.8 months, 95% confidence interval = 34.5 to not reached, two-sided P = .94). Loss of heterozygosity was found in 60.0% of BRCA1/2. PGAs frequently occur in pancreas exocrine neoplasms and involve multiple genes beyond those previously associated with hereditary pancreatic cancer. These PGAs are therapeutically actionable in about 5% to 10% of patients. These data support routinely offering GT in all pancreatic ductal adenocarcimona patients with a broad panel of known hereditary cancer predisposition genes. |
| Author | Wong, Winston Capanu, Marinela Ravichandran, Vignesh Offit, Kenneth Abou-Alfa, Ghassan K Askan, Gokce Kelsen, David P Hyman, David M O'Reilly, Eileen M Vijai, Joseph Yu, Kenneth H Salo-Mullen, Erin Zehir, Ahmet Robson, Mark E Lowery, Maeve A Varghese, Anna M Maynard, Hannah Tjan, Catherine Berger, Michael F Allen, Peter J Lee, Jonathan W Kemel, Yelena Arnold, Angela G Kaufmann, Erica Covington, Christina Leach, Steven D Brenner, Robin Mandelker, Diana Jordan, Emmet J Klimstra, David S Mukherjee, Semanti Stadler, Zsofia K Iacobuzio-Donahue, Christine A |
| Author_xml | – sequence: 1 givenname: Maeve A surname: Lowery fullname: Lowery, Maeve A organization: David M. Rubenstein Center for Pancreatic Cancer Research – sequence: 2 givenname: Winston surname: Wong fullname: Wong, Winston organization: Department of Medicine, Weill Cornell – sequence: 3 givenname: Emmet J surname: Jordan fullname: Jordan, Emmet J organization: Department of Medicine – sequence: 4 givenname: Jonathan W surname: Lee fullname: Lee, Jonathan W organization: Department of Medicine – sequence: 5 givenname: Yelena surname: Kemel fullname: Kemel, Yelena organization: Robert and Kate Niehaus Center for Inherited Genomics – sequence: 6 givenname: Joseph surname: Vijai fullname: Vijai, Joseph organization: Center for Molecular Oncology – sequence: 7 givenname: Diana surname: Mandelker fullname: Mandelker, Diana organization: Department of Pathology – sequence: 8 givenname: Ahmet surname: Zehir fullname: Zehir, Ahmet organization: Center for Molecular Oncology – sequence: 9 givenname: Marinela surname: Capanu fullname: Capanu, Marinela organization: Department of Epidemiology and Biostatistics – sequence: 10 givenname: Erin surname: Salo-Mullen fullname: Salo-Mullen, Erin organization: Robert and Kate Niehaus Center for Inherited Genomics – sequence: 11 givenname: Angela G surname: Arnold fullname: Arnold, Angela G organization: Robert and Kate Niehaus Center for Inherited Genomics – sequence: 12 givenname: Kenneth H surname: Yu fullname: Yu, Kenneth H organization: Department of Medicine, Weill Cornell – sequence: 13 givenname: Anna M surname: Varghese fullname: Varghese, Anna M organization: Department of Medicine, Weill Cornell – sequence: 14 givenname: David P surname: Kelsen fullname: Kelsen, David P organization: Department of Medicine, Weill Cornell – sequence: 15 givenname: Robin surname: Brenner fullname: Brenner, Robin organization: David M. Rubenstein Center for Pancreatic Cancer Research – sequence: 16 givenname: Erica surname: Kaufmann fullname: Kaufmann, Erica organization: David M. Rubenstein Center for Pancreatic Cancer Research – sequence: 17 givenname: Vignesh surname: Ravichandran fullname: Ravichandran, Vignesh organization: Center for Molecular Oncology – sequence: 18 givenname: Semanti surname: Mukherjee fullname: Mukherjee, Semanti organization: Robert and Kate Niehaus Center for Inherited Genomics – sequence: 19 givenname: Michael F surname: Berger fullname: Berger, Michael F organization: Department of Pathology – sequence: 20 givenname: David M surname: Hyman fullname: Hyman, David M organization: Department of Medicine, Weill Cornell – sequence: 21 givenname: David S surname: Klimstra fullname: Klimstra, David S organization: Department of Pathology – sequence: 22 givenname: Ghassan K surname: Abou-Alfa fullname: Abou-Alfa, Ghassan K organization: Department of Medicine, Weill Cornell – sequence: 23 givenname: Catherine surname: Tjan fullname: Tjan, Catherine organization: Department of Medicine – sequence: 24 givenname: Christina surname: Covington fullname: Covington, Christina organization: Department of Medicine – sequence: 25 givenname: Hannah surname: Maynard fullname: Maynard, Hannah organization: Department of Medicine – sequence: 26 givenname: Peter J surname: Allen fullname: Allen, Peter J organization: Department of Surgery – sequence: 27 givenname: Gokce surname: Askan fullname: Askan, Gokce organization: Department of Pathology – sequence: 28 givenname: Steven D surname: Leach fullname: Leach, Steven D organization: Department of Surgery – sequence: 29 givenname: Christine A surname: Iacobuzio-Donahue fullname: Iacobuzio-Donahue, Christine A organization: David M. Rubenstein Center for Pancreatic Cancer Research – sequence: 30 givenname: Mark E surname: Robson fullname: Robson, Mark E organization: Robert and Kate Niehaus Center for Inherited Genomics – sequence: 31 givenname: Kenneth surname: Offit fullname: Offit, Kenneth organization: Robert and Kate Niehaus Center for Inherited Genomics – sequence: 32 givenname: Zsofia K surname: Stadler fullname: Stadler, Zsofia K organization: Department of Medicine, Weill Cornell – sequence: 33 givenname: Eileen M surname: O'Reilly fullname: O'Reilly, Eileen M organization: Department of Medicine, Weill Cornell |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/29506128$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNkD1PwzAQhi1URGlhYkceWULti_PhsapKQaqgA4gJRY5zEa4Su9hJRf89AYrELffofR_dcBMyss4iIVec3XIm49nWajOrtgcG4oScc5GyCDhLRv94TCYhbNkwEsQZGYNMWMohPydvG-_CDnVn9kiXe9X0qjPOUlfTFfq2MRbpvOnQ_8SBGks3A6LtAn013Ttdfjrtv62Nstrj0Gn6iG7XqNCGC3Jaqybg5XFPycvd8nlxH62fVg-L-TrScc67qBQqRajLUpc14wy5lBpyBYlkWarqKk4kZ3key7QSsspAoACdxRKgQswSDVNy83t3591Hj6ErWhM0No2y6PpQAOMcsiTlYlCvj2pftlgVO29a5Q_F30vgC6TtZaQ |
| CitedBy_id | crossref_primary_10_1053_j_gastro_2019_02_037 crossref_primary_10_3390_cancers14122950 crossref_primary_10_3389_fsurg_2022_866173 crossref_primary_10_1016_j_hpb_2022_09_003 crossref_primary_10_3389_fonc_2022_989077 crossref_primary_10_24060_2076_3093_2022_12_1_48_55 crossref_primary_10_1016_j_ejca_2023_113338 crossref_primary_10_1016_j_gim_2024_101243 crossref_primary_10_1053_j_gastro_2018_12_039 crossref_primary_10_1016_j_cgh_2020_05_058 crossref_primary_10_21294_1814_4861_2025_24_3_149_161 crossref_primary_10_3389_fonc_2022_880643 crossref_primary_10_3390_cancers13225612 crossref_primary_10_3390_cancers14040897 crossref_primary_10_3748_wjg_v27_i17_1943 crossref_primary_10_1016_j_ctrv_2019_101895 crossref_primary_10_1016_j_ctrv_2022_102357 crossref_primary_10_1136_gutjnl_2019_319352 crossref_primary_10_14309_ctg_0000000000000414 crossref_primary_10_3390_jpm12122076 crossref_primary_10_1053_j_seminoncol_2021_02_006 crossref_primary_10_1200_GO_25_00016 crossref_primary_10_1016_j_pan_2022_05_003 crossref_primary_10_1136_jmedgenet_2021_108054 crossref_primary_10_1016_j_pan_2024_09_018 crossref_primary_10_1002_cncr_31951 crossref_primary_10_1002_ijc_33210 crossref_primary_10_1007_s10555_021_09983_1 crossref_primary_10_1002_cncr_34269 crossref_primary_10_1007_s00761_019_0552_y crossref_primary_10_1093_jnci_djab038 crossref_primary_10_1097_MPA_0000000000002104 crossref_primary_10_3390_biomedicines10112705 crossref_primary_10_1016_j_ogc_2021_11_005 crossref_primary_10_1055_a_1864_2538 crossref_primary_10_1200_EDBK_238977 crossref_primary_10_3390_genes11091098 crossref_primary_10_1158_1078_0432_CCR_20_1788 crossref_primary_10_1016_j_yamp_2022_07_002 crossref_primary_10_1055_a_1856_7346 crossref_primary_10_1186_s13053_021_00178_x crossref_primary_10_1016_j_prp_2020_153309 crossref_primary_10_1093_jjco_hyad131 crossref_primary_10_3390_cells11193068 crossref_primary_10_1007_s00292_023_01288_0 crossref_primary_10_1159_000543997 crossref_primary_10_3390_cancers14081866 crossref_primary_10_1002_cncr_32077 crossref_primary_10_1016_j_suc_2024_03_002 crossref_primary_10_1038_s41379_020_0629_6 crossref_primary_10_1016_j_surg_2020_06_038 crossref_primary_10_1177_17588359221083050 crossref_primary_10_1177_17562848231171456 crossref_primary_10_1186_s13058_020_01273_y crossref_primary_10_1007_s00535_021_01806_y crossref_primary_10_1016_j_gpb_2023_02_004 crossref_primary_10_1002_cam4_2973 crossref_primary_10_1001_jamanetworkopen_2021_14753 crossref_primary_10_3390_cancers13184716 crossref_primary_10_1016_j_path_2022_05_004 crossref_primary_10_1172_JCI128227 crossref_primary_10_1016_j_jtho_2020_08_017 crossref_primary_10_1089_pancan_2020_0010 crossref_primary_10_1038_s41416_019_0582_7 crossref_primary_10_1097_JS9_0000000000000877 crossref_primary_10_3390_cancers12113346 crossref_primary_10_5858_arpa_2020_0047_RA crossref_primary_10_7759_cureus_22575 crossref_primary_10_1016_j_giec_2021_09_001 crossref_primary_10_1002_cncr_32740 crossref_primary_10_1002_mgg3_2170 crossref_primary_10_1016_j_ebiom_2020_103033 crossref_primary_10_3390_cancers16010056 crossref_primary_10_1093_jnci_djaa004 crossref_primary_10_3390_cancers13205136 crossref_primary_10_3390_jcm14020367 crossref_primary_10_1016_j_pan_2021_04_004 crossref_primary_10_3390_genes11010108 crossref_primary_10_1053_j_gastro_2023_02_012 crossref_primary_10_1055_a_2338_3533 crossref_primary_10_3390_cancers14184447 crossref_primary_10_1016_j_hpb_2020_03_022 crossref_primary_10_1200_JCO_18_01512 crossref_primary_10_1245_s10434_025_17062_w crossref_primary_10_3390_biomedicines9081024 crossref_primary_10_1002_ijc_33883 crossref_primary_10_3390_cancers13020198 crossref_primary_10_7759_cureus_43261 crossref_primary_10_1007_s10549_018_4980_y crossref_primary_10_1016_j_pbiomolbio_2025_02_003 crossref_primary_10_1007_s11938_022_00386_x crossref_primary_10_1186_s12964_025_02281_1 crossref_primary_10_1016_j_prp_2023_154336 crossref_primary_10_1016_j_bbcan_2023_188914 crossref_primary_10_1007_s12094_020_02350_6 crossref_primary_10_1007_s13187_019_01623_1 crossref_primary_10_1097_MPA_0000000000002170 crossref_primary_10_1200_EDBK_321255 crossref_primary_10_1016_j_ejca_2024_115051 crossref_primary_10_3390_biomedicines11041069 crossref_primary_10_1188_25_ONF_293_301 crossref_primary_10_1016_j_esmogo_2025_100218 crossref_primary_10_1053_j_seminoncol_2021_01_005 crossref_primary_10_1016_j_hoc_2022_07_008 crossref_primary_10_1016_j_hoc_2022_07_005 crossref_primary_10_3390_cancers14102453 crossref_primary_10_1002_cncr_33812 crossref_primary_10_1007_s10689_024_00372_5 crossref_primary_10_1038_s41575_021_00463_z crossref_primary_10_3390_diagnostics11061046 crossref_primary_10_7554_eLife_71137 crossref_primary_10_1016_j_ejca_2018_09_004 crossref_primary_10_1016_j_pan_2023_10_017 crossref_primary_10_1097_MPA_0000000000001888 crossref_primary_10_2337_db22_0942 crossref_primary_10_14309_ctg_0000000000000668 crossref_primary_10_1158_1940_6207_CAPR_21_0189 crossref_primary_10_1186_s13053_021_00190_1 crossref_primary_10_1016_j_clcc_2022_10_002 crossref_primary_10_1016_j_breast_2022_06_003 crossref_primary_10_1016_j_pan_2022_08_004 crossref_primary_10_1089_clinomi_07_01_23 crossref_primary_10_1186_s12014_019_9251_3 crossref_primary_10_1056_NEJMcpc2201231 crossref_primary_10_3390_biomedicines10092056 crossref_primary_10_3748_wjg_v28_i45_6420 crossref_primary_10_1158_1078_0432_CCR_20_0418 crossref_primary_10_2217_pgs_2018_0073 crossref_primary_10_33667_2078_5631_2025_14_26_30 crossref_primary_10_1016_j_ccell_2020_12_021 crossref_primary_10_1007_s10689_018_0106_2 crossref_primary_10_3390_jimaging9080149 crossref_primary_10_1007_s10689_024_00383_2 crossref_primary_10_1016_j_bpg_2021_101783 crossref_primary_10_1177_17588359231189127 crossref_primary_10_1016_j_jgo_2020_01_001 crossref_primary_10_1016_j_soc_2021_06_002 crossref_primary_10_1007_s40291_022_00614_1 crossref_primary_10_1002_gcc_22932 crossref_primary_10_1007_s10147_025_02713_5 crossref_primary_10_1038_s41598_024_71884_4 crossref_primary_10_1002_onco_13968 crossref_primary_10_1016_S2468_1253_19_30175_X crossref_primary_10_1186_s12885_024_12722_8 crossref_primary_10_1038_s41598_025_86249_8 crossref_primary_10_1016_j_tige_2024_08_001 crossref_primary_10_1002_ijc_33317 crossref_primary_10_1093_jnci_djaf150 crossref_primary_10_3748_wjg_v28_i45_6421 crossref_primary_10_1158_1078_0432_CCR_22_1483 crossref_primary_10_18027_2224_5057_2018_8_3_5_12 crossref_primary_10_1002_jso_26994 crossref_primary_10_3389_fonc_2023_1151090 crossref_primary_10_3390_ijms23094709 crossref_primary_10_1007_s10048_019_00597_y crossref_primary_10_2147_CMAR_S211151 crossref_primary_10_3390_onco5030037 |
| ContentType | Journal Article |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1093/jnci/djy024 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1460-2105 |
| ExternalDocumentID | 29506128 |
| Genre | Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural |
| GrantInformation_xml | – fundername: NCI NIH HHS grantid: R25 CA020449 – fundername: NCI NIH HHS grantid: P30 CA008748 |
| GroupedDBID | --- -E4 -~X .2P .I3 .XZ .ZR 08P 0R~ 1TH 29L 2WC 354 4.4 482 48X 5GY 5RE 5VS 5WD 70D 96U AABZA AACZT AAHTB AAJKP AAJQQ AAMVS AAOGV AAPNW AAPQZ AAPXW AARHZ AAUAY AAUQX AAVAP AAWTL ABCQX ABDFA ABEJV ABEUO ABGNP ABIXL ABJNI ABKDP ABNHQ ABNKS ABOCM ABPEJ ABPPZ ABPTD ABQLI ABQNK ABVGC ABXVV ABZBJ ACBMB ACGFO ACGFS ACGOD ACKOT ACNCT ACPRK ACUFI ACUTJ ACUTO ACYHN ADBBV ADEYI ADEZT ADGZP ADHKW ADHZD ADIPN ADNBA ADOCK ADQBN ADRTK ADVEK ADYVW AEGPL AEJOX AEKSI AEMDU AEMQT AENZO AEPUE AETBJ AEWNT AFAZI AFFNX AFFZL AFIYH AFOFC AFRAH AFXAL AFYAG AGINJ AGKEF AGORE AGSYK AGUTN AHMBA AHMMS AHXPO AIAGR AIJHB AJBYB AJEEA AJNCP ALMA_UNASSIGNED_HOLDINGS ALUQC ALXQX APIBT APWMN ATGXG BAWUL BAYMD BCRHZ BEYMZ BTRTY BVRKM C45 CDBKE CGR CS3 CUY CVF CZ4 DAKXR DIK DILTD DU5 D~K E3Z EBS ECM EE~ EIF EMOBN ENERS F5P F8P F9B FECEO FLUFQ FOEOM FOTVD FQBLK GAUVT GJXCC GX1 H13 H5~ HAR HW0 HZ~ IH2 IOX J21 JXSIZ KAQDR KBUDW KOP KQ8 KSI KSN L7B M-Z MHKGH ML0 N9A NGC NOMLY NOYVH NPM NU- OAUYM OAWHX OBH OCB OCZFY ODMLO ODZKP OGEVE OHH OJQWA OJZSN OK1 OPAEJ OVD OWPYF P2P PAFKI PEELM PQQKQ Q.- Q1. Q5Y R44 RD5 RNS ROL ROX ROZ RUSNO RW1 RXO TCURE TEORI TJX TMA TR2 TWZ UDS UPT VVN W8F WH7 WOQ X7H YAYTL YKOAZ YQT YXANX ZKX ZRR ZY1 ~91 ~H1 7X8 |
| ID | FETCH-LOGICAL-c381t-b4a6e2fbbcbf010e199c28a259076afd3591088396d49d724e42c73922dee75c2 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 188 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000455206400004&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1460-2105 |
| IngestDate | Sun Sep 28 07:09:08 EDT 2025 Mon Jul 21 06:06:10 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 10 |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c381t-b4a6e2fbbcbf010e199c28a259076afd3591088396d49d724e42c73922dee75c2 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| OpenAccessLink | https://academic.oup.com/jnci/article-pdf/110/10/1067/26692365/djy024.pdf |
| PMID | 29506128 |
| PQID | 2011275614 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_2011275614 pubmed_primary_29506128 |
| PublicationCentury | 2000 |
| PublicationDate | 2018-10-01 |
| PublicationDateYYYYMMDD | 2018-10-01 |
| PublicationDate_xml | – month: 10 year: 2018 text: 2018-10-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | JNCI : Journal of the National Cancer Institute |
| PublicationTitleAlternate | J Natl Cancer Inst |
| PublicationYear | 2018 |
| SSID | ssj0000924 |
| Score | 2.630654 |
| Snippet | Identification of pathogenic germline alterations (PGAs) has important clinical and therapeutic implications in pancreas cancer. We performed comprehensive... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 1067 |
| SubjectTerms | Adult Aged Aged, 80 and over Alleles Antineoplastic Agents - pharmacology Antineoplastic Agents - therapeutic use Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biomarkers, Tumor Female Genetic Association Studies Genetic Predisposition to Disease Germ-Line Mutation Heterozygote Humans Kaplan-Meier Estimate Loss of Heterozygosity Male Middle Aged Pancreas, Exocrine - pathology Pancreatic Neoplasms - genetics Pancreatic Neoplasms - mortality Pancreatic Neoplasms - pathology Pancreatic Neoplasms - therapy |
| Title | Prospective Evaluation of Germline Alterations in Patients With Exocrine Pancreatic Neoplasms |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/29506128 https://www.proquest.com/docview/2011275614 |
| Volume | 110 |
| WOSCitedRecordID | wos000455206400004&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LS8QwEA7qinjx_VhfRPAatk2TtDnJIqse3NKD4l6ktGmCXbRdt6vov3fSdt2TIHgptNBShsnMN5l83yB0AQgeYl4gCVPCthldRhKjBUkNc7Wfcu6Jmih854dhMBrJqN1wq9pjlfOYWAfqrFR2j7xnE5WVKnfZ5eSN2KlRtrvajtBYRh0PoIxdmP5ooRbuyGaoLRMOgdKGt_w8KOJ740LlvWz85Viq-2_Yss4x15v__bsttNGiS9xv3GEbLeliB60N2_75LnqKpuWcW4kHP0LfuDT4BkK0hZy4_1ILLVt3xHmBo0Z4tcKP-ewZDz5LZfmC8Lho8KbCoT2EnlSv1R56uB7cX92SdsACUZCoZyRlidDUpKlKDdRl2pVS0SCBisjxRWIyjwOYCABCiYzJzKdMM6p8QFQ009rniu6jlaIs9CHCVkYuCZSBTxqWJVSqjAbCADjjxnM076LzueFicGDblUgKXb5X8cJ0XXTQWD-eNEobMZXcQrDg6A9vH6N1uGm0at0T1DGwfPUpWlUfs7yantWeAdcwGn4DOGzEUQ |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Prospective+Evaluation+of+Germline+Alterations+in+Patients+With+Exocrine+Pancreatic+Neoplasms&rft.jtitle=JNCI+%3A+Journal+of+the+National+Cancer+Institute&rft.au=Lowery%2C+Maeve+A&rft.au=Wong%2C+Winston&rft.au=Jordan%2C+Emmet+J&rft.au=Lee%2C+Jonathan+W&rft.date=2018-10-01&rft.issn=1460-2105&rft.eissn=1460-2105&rft.volume=110&rft.issue=10&rft.spage=1067&rft_id=info:doi/10.1093%2Fjnci%2Fdjy024&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1460-2105&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1460-2105&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1460-2105&client=summon |